31 Jul, EOD - Indian

Nifty Bank 55961.95 (-0.34)

Nifty IT 35301.6 (-0.51)

Nifty 50 24768.35 (-0.35)

Nifty Midcap 100 57400.55 (-0.93)

SENSEX 81185.58 (-0.36)

Nifty Pharma 22771.05 (-1.31)

Nifty Next 50 67096.15 (-0.50)

Nifty Smallcap 100 17966.85 (-1.05)

31 Jul, EOD - Global

NIKKEI 225 40928.58 (-0.34)

HANG SENG 24805.52 (0.13)

S&P 6377.75 (-0.13)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(21 Jul 2025, 10:26)

Anthem Biosciences jumps on debut

Shares of Anthem Biosciences were currently trading at Rs 726.35 at 10:21 IST on the BSE, representing a premium of 27.43% compared with the issue price of Rs 570.


The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price.

So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far.

The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share.

The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%.

Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs.

Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors.

The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.

More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +